Subcutaneous alemtuzumab for multiple sclerosis

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

C Tur has received honoraria and support for travel from Serono Foundation, Sanofi-Aventis and Teva Pharmaceutical Industries Ltd. X Montalban serves on scientific advisory boards for Novartis, Teva Pharmaceutical Industries Ltd., Merck Serono, Biogen Idec and Bayer Schering Pharma; has received funding for travel and speaker honoraria from Novartis, Teva Pharmaceutical Industries Ltd., Merck Serono, Biogen Idec, Sanofi-Aventis and Bayer Schering Pharma; serves on the editorial boards of Multiple Sclerosis, Journal of Neurology, The International MS Journal, Revista de Neurología, and Therapeutic Advances in Neurological Disorders; serves as a consultant to Bayer Schering Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Novartis, Almirall, and Eli Lilly and Company; and has received research support for clinical trials from Genentech, Inc., Genzyme Corporation, Wyeth and the above listed, and receives research support from the Fundació Esclerosi Múltiple (FEM). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.